Shprintzen–Goldberg syndrome

From WikiMD's WELLNESSPEDIA

Autosomal dominant - en

Shprintzen–Goldberg syndrome (SGS) is a rare genetic disorder characterized by a combination of distinctive facial features, skeletal abnormalities, and various other physical and developmental anomalies. It was first described by Robert Shprintzen and Richard Goldberg in 1982.

Signs and Symptoms[edit]

Individuals with Shprintzen–Goldberg syndrome typically present with a range of symptoms, which may include:

Genetics[edit]

Shprintzen–Goldberg syndrome is typically caused by mutations in the SKI gene, which plays a role in the TGF-beta signaling pathway. This pathway is crucial for the regulation of cell growth and development. The syndrome is inherited in an autosomal dominant manner, meaning that a single copy of the mutated gene is sufficient to cause the disorder.

Diagnosis[edit]

Diagnosis of Shprintzen–Goldberg syndrome is based on clinical evaluation, identification of characteristic physical features, and genetic testing to confirm mutations in the SKI gene. Prenatal diagnosis may be possible if a known mutation is present in the family.

Treatment[edit]

There is no cure for Shprintzen–Goldberg syndrome, and treatment is primarily supportive and symptomatic. Management may involve:

  • Surgical intervention for craniosynostosis and scoliosis
  • Regular monitoring and management of cardiovascular issues
  • Physical therapy to improve joint mobility and muscle strength
  • Educational support and developmental therapies for intellectual disabilities

Prognosis[edit]

The prognosis for individuals with Shprintzen–Goldberg syndrome varies depending on the severity of symptoms and associated complications. With appropriate medical care and support, many individuals can lead relatively normal lives.

Related Pages[edit]

References[edit]


External Links[edit]

-


Medical condition





















Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.